Takeda Pharmaceutical Co., Ltd. (TKPHF)
Takeda Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company whose common stock is listed on OTC Markets under the symbol TKPH.F. The company is engaged in the research, development, manufacturing, marketing, and out-licensing of prescription medicines in Japan and international markets. Its portfolio spans gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Takeda’s branded products include Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Takhzyro, Livtencity, ADZYNMA, FRUZAQLA, Ninlaro, Velcade, QDENGA, and Alunbrig, among others. The company also maintains a broad network of in-licensing, collaboration, and licensing agreements with multiple biotechnology and pharmaceutical partners, supporting its research and development activities. Founded in 1781 and headquartered in Tokyo, Takeda has a long operating history in the global healthcare sector.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-TKPH.F
|
$30.70
|
-11.5% Downside
|
Fair
|
—
|
—
|
—
|
Good
|
—
|
—
|
1.32
|
3.5%
|
July 30, 2026
|
-56.8x
|
1.2x
|
1.9x
|
53.952 B
|
85.313 B
|
38.7%
|
99.9%
|
5.5
|
-204.7%
|
-567.9%
|
